Clinical and Biological Signs of Dapagliflozin Overdose in ICU Patients With Metformin Poisoning

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT07193069

Enrollment

Registered

2025-09-25

Start date

2025-04-11

Completion date

2026-04-11

Last updated

2025-09-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dapagliflozin, Diabetic Ketoacidosis, Drug Overdose, Intensive Care Units, Lactic Acidosis, Metformin

Brief summary

This study looks at patients admitted to intensive care for drug poisoning involving metformin, a common diabetes medication. Researchers will compare two groups: patients who overdosed on metformin alone and those who took both metformin and dapagliflozin, another diabetes drug. The goal is to find clinical or laboratory signs that could help doctors quickly recognize a dapagliflozin overdose in this context, which could improve treatment and patient outcomes.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Inclusion criteria

* Adults aged 18 years or older * Admission to an intensive care unit (ICU) due to acute drug poisoning * Documented exposure to either: * Metformin alone * Metformin in combination with dapagliflozin

Exclusion criteria

* Patients under 18 years of age * No exposure to metformin * Exposure to dapagliflozin without metformin

Design outcomes

Primary

Measure	Time frame
Identification of clinical and biological differences between patients admitted to intensive care for metformin overdose alone versus those with combined metformin and dapagliflozin overdose.	10 years

Countries

France

Outcome results